
In the year ended Jun 2022, Procter & Gamble Health generated ₹170 crore from operating activities, invested ₹26 crore and paid out ₹289 crore on financing activities. Net cash flow for the year was -₹145 crore. Free cash flow was ₹132 crore.
Financial years, newest first. Negative figures are cash outflows.
| Item | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activities | 170 | 236 | 228 | 1,400 | 1,400 | 1,400 | 1,400 | 338 |
| Cash from investing activities | -26 | -22 | -7 | -600 | -600 | -600 | -600 | 1 |
| Cash from financing activities | -289 | -98 | -418 | -550 | -550 | -550 | -550 | -344 |
| Net cash flow | -145 | 116 | -197 | 250 | 250 | 250 | 250 | -5 |
| Capital expenditure | — | — | — | — | — | — | — | — |
| Free cash flow | 132 | 194 | 207 | 950 | 950 | 950 | 950 | 322 |
Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Procter & Gamble Health's cash flow from operating activities was ₹170 crore in the year ended Jun 2022, fell 27.97% from ₹236 crore in Jun 2023.
Procter & Gamble Health's free cash flow — operating cash flow minus capital expenditure — was ₹132 crore in Jun 2022.
Net cash used in investing activities was ₹26 crore in Jun 2022. This covers capital expenditure, acquisitions and the purchase or sale of investments.
Track PGHL live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.